Jean Liu Biography and Net Worth

With more than 20 years of experience in the biotechnology industry, Jean holds deep expertise in legal and business leadership. She oversees all aspects of the legal, compliance, and intellectual property functions at Seagen and serves as Corporate Secretary, advising on strategic matters.

Previously, Jean was the Vice President of General Counsel at Halozyme Therapeutics and the Chief Legal Officer and Corporate Secretary at Durect Corporation. Earlier in her career, Jean was an attorney at Pillsbury, Madison & Sutro (now Pillsbury Winthrop) and Venture Law Group, where she advised early-stage companies on technology transfer, licensing, patents, and copyright and trademark litigation.

Jean holds a J.D. from Columbia University, where she was a Harlan Fiske Stone Scholar. She also earned an M.S. in Biology from Stanford University and a B.S. in Cellular and Molecular Biology with highest distinction from the University of Michigan. She serves as a member of the board of directors for Connect Biopharma Holdings Ltd.

What is Jean I. Liu's net worth?: The estimated net worth of Jean I. Liu is at least $19.85 million as of April 17th, 2023. Ms. Liu owns 86,763 shares of Seagen stock worth more than $19,846,169 as of April 24th. This net worth evaluation does not reflect any other investments that Ms. Liu may own. Additionally, Ms. Liu receives a salary of $1,230,000.00 as EVP at Seagen. Learn More about Jean I. Liu's net worth.
How old is Jean I. Liu?: Ms. Liu is currently 55 years old. There are 4 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who is 67 years old. Learn More on Jean I. Liu's age.
What is Jean I. Liu's salary?: As the EVP of Seagen Inc., Ms. Liu earns $1,230,000.00 per year. There are 3 executives that earn more than Ms. Liu. The highest earning executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who commands a salary of $2,480,000.00 per year. Learn More on Jean I. Liu's salary.
How do I contact Jean I. Liu?: The corporate mailing address for Ms. Liu and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Jean I. Liu's contact information.
Has Jean I. Liu been buying or selling shares of Seagen?: Jean I. Liu has not been actively trading shares of Seagen during the last ninety days. Learn More on Jean I. Liu's trading history.
Who are Seagen's active insiders?: Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.
Are insiders buying or selling shares of Seagen?: In the last twelve months, insiders at the biotechnology company sold shares 20 times. They sold a total of 70,520 shares worth more than $14,429,678.66. The most recent insider tranaction occured on November, 10th when CEO David R Epstein sold 10,620 shares worth more than $2,262,166.20. Insiders at Seagen own 25.9% of the company. Learn More about insider trades at Seagen.
Information on this page was last updated on 11/10/2023.

Jean I. Liu Insider Trading History at Seagen

Jean I. Liu Buying and Selling Activity at Seagen

Seagen Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

2 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

Jean Liu Biography and Net Worth

What is Jean I. Liu's net worth?

How old is Jean I. Liu?

What is Jean I. Liu's salary?

How do I contact Jean I. Liu?

Has Jean I. Liu been buying or selling shares of Seagen?

Who are Seagen's active insiders?

Are insiders buying or selling shares of Seagen?